Short ratio of Supernus Pharmaceuticals, Inc.
Short ratio is calculated by dividing the number of shares sold short by the average daily trading volume, generally over the last 30 trading days. The ratio represents the number of days it takes short sellers on average to repurchase all the borrowed shares. The ratio is used by both fundamental and technical traders to identify trends.
The percentage represents the number of days it takes short sellers on average to repurchase all the borrowed shares. Short selling is the practice of selling securities or other financial instruments that are not currently owned, and subsequently repurchasing them. In the event of an interim price decline, the short seller profits, since the cost of (re)purchase is less than the proceeds received upon the initial (short) sale. Conversely, the short position closes out at a loss if the price of a shorted instrument rises prior to repurchase. A high short ratio can be an indicator that there will be some buying pressure on the security that would increase its price.
Short ratio of companies in the Health Care sector on NASDAQ compared to Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
- Supernus Pharmaceuticals, Inc., 1550 East Gude Drive, Rockville 20850, United States
Companies with short ratio similar to Supernus Pharmaceuticals
|MDR McDermott International, Inc.||NYSE > Capital Goods > Metal Fabrications||8.43|
|ESND Essendant Inc.||NASDAQ > Consumer Services > Paper||8.45|
|CNXN PC Connection, Inc.||NASDAQ > Consumer Services > Catalog/Specialty Distribution||8.46|
|CDXS Codexis, Inc.||NASDAQ > Basic Industries > Major Chemicals||8.47|
|GHDX Genomic Health, Inc.||NASDAQ > Health Care > Medical Specialities||8.47|
|CCJ Cameco Corporation||NYSE > Basic Industries > Precious Metals||8.48|
|SUPN Supernus Pharmaceuticals, Inc.||NASDAQ > Health Care > Major Pharmaceuticals||8.49|
|AAMC Altisource Asset Management Corp||NYSEMKT > Finance > Real Estate||78.83|
|UNB Union Bankshares, Inc.||NASDAQ > Finance > Major Banks||79.46|
|CIA Citizens, Inc.||NYSE > Finance > Life Insurance||85.59|
|MAYS J. W. Mays, Inc.||NASDAQ > Consumer Services > Building operators||99.69|
|ATLC Atlanticus Holdings Corporation||NASDAQ > Finance > Finance: Consumer Services||103.09|
|UONEK Urban One, Inc.||NASDAQ > Consumer Services > Broadcasting||154.06|